A Phase 3 interventional study of ponesimod and teriflunomide in Multiple Sclerosis, sponsored by Actelion. Completed at 162 sites in 28 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Multiple Sclerosis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis · Russian Federation.
Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, this one is the 11th largest by enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2015, is one of 40 in phase 3, and was the 64th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →None of the 86 studies in Multiple Sclerosis with a site in Russian Federation is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 34 · Phase 3 42 · Phase 4 5
First in 2002; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,133 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 402 across the 83 interventional studies, 307 across the 3 observational. Of the 82 that completed or were terminated, 65 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 7 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male and female subjects aged 18 to 55 years with established diagnosis of MS McDonald 2010 with relapsing course from onset (i.e., RRMS and SPMS with superimposed relapses).
Subjects must have active disease evidenced by one or more MS attacks with onset within the period of 12 to 1 months prior to randomization, or by two or more MS attacks with onset within the 24 to 1 months prior to randomization, or with one or more gadolinium-enhancing (Gd+) lesion(s) of the brain on an MRI performed within 6 months prior to randomization.
Enrolled subjects must be ambulatory (EDSS score of up to 5.5 inclusive) and may be treatment-naïve or previously treated with MS disease modifying therapy.
Exclusion Criteria:
Subjects with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic,ophthalmological conditions) or lactating or pregnant women are not eligible to enter the study.
Subjects with to MRI or with medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study are not eligible to enter the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects to receive 20 mg ponesimod
Drug: ponesimod
Subjects to receive 14 mg teriflunomide
Drug: teriflunomide
film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
Also known as: ACT-128800
film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
Annualized Confirmed Relapse Rate
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual,Brain Stem,Pyramidal,Cerebellar,Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).
Time frame: From randomization to end of study (Week 108)
Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108
The FSIQ-RMS is a 20-item Patient Reported Outcomes (PRO) measure to evaluate fatigue-related symptoms and the impacts of those symptoms on the lives of people. The FSIQ-RMS symptom domain (FSIQ-RMS-S) consists of seven items assessing fatigue-related symptoms daily with a recall period of 24 hours measured on an 11-point numeric rating scale; the (normalized) symptom domain score ranges from 0 to 100 with a higher score indicating greater fatigue. This domain was completed on 7 consecutive days. A negative change from baseline indicates an improvement in fatigue symptoms.
Time frame: Baseline to Week 108
Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108
CUALs was calculated as sum of new Gadolinium-enhanced (Gd+) T1 lesions plus new or enlarging T2 lesions (without double-counting of lesions) from baseline based on the Magnetic resonance imaging (MRI) scans up to Week 108. Average number of lesions per year were reported.
Time frame: Baseline to Week 108
12-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS
A 12-week CDA was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).
Time frame: Baseline to Week 60 and 108 Weeks
24-Week Confirmed Disability Accumulation (CDA) Assessed From Baseline to EOS
A 24-week CDA was defined as an increase of at least 1.5 in EDSS for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score \>= 5.5, which was confirmed after 24 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. The EDSS is an ordinal scale ranging from 0 (normal neurological exam) to 10 (death to MS).
Time frame: Baseline to 60 Weeks and 108 Weeks
| Milestone | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Started | 567 | 566 |
| Treated | 565 | 566 |
| Completed | 490 | 495 |
| Not completed | 77 | 71 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Withdrawal by subject | 41 | 36 |
| Withdrew: Lack of efficacy | 3 | 10 |
| Withdrew: Adverse event | 13 | 3 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Other | 18 | 17 |
Relapse: occurrence of acute episode of one or more new symptoms or worsened symptoms of Multiple sclerosis (MS), not associated with fever/infection and lasting 24 hours after stable 30 days period. Confirmed relapse: increase from baseline at least 0.5 point Expanded Disability Status Scale (EDSS) score or increase of one point in one, two or three Functional Systems (FS), excluding bowel/bladder and cerebral/mental FS. EDSS and FS scores are based on neurological examination for assessing its impairment in MS. Among eight FS, seven are ordinal clinical rating scales ranging from 0-5 or 6 with higher scale indicates overall functional impairment assessing Visual,Brain Stem,Pyramidal,Cerebellar,Sensory, Bowel/Bladder and Cerebral functions. Rating individual FS scores is used to rate EDSS in conjunction with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10(death due to MS).
| relapses per year | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Annualized Confirmed Relapse Rate | 0.202 (0.165 to 0.246) | 0.290 (0.244 to 0.345) |
The FSIQ-RMS is a 20-item Patient Reported Outcomes (PRO) measure to evaluate fatigue-related symptoms and the impacts of those symptoms on the lives of people. The FSIQ-RMS symptom domain (FSIQ-RMS-S) consists of seven items assessing fatigue-related symptoms daily with a recall period of 24 hours measured on an 11-point numeric rating scale; the (normalized) symptom domain score ranges from 0 to 100 with a higher score indicating greater fatigue. This domain was completed on 7 consecutive days. A negative change from baseline indicates an improvement in fatigue symptoms.
| score on scale | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Change From Baseline in Fatigue-related Symptoms as Measured by the Symptoms Domain of the Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS) Score to Week 108 | -0.01 (-1.60 to 1.58) | 3.56 (1.96 to 5.16) |
CUALs was calculated as sum of new Gadolinium-enhanced (Gd+) T1 lesions plus new or enlarging T2 lesions (without double-counting of lesions) from baseline based on the Magnetic resonance imaging (MRI) scans up to Week 108. Average number of lesions per year were reported.
| lesions per year | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Cumulative Number of Combined Unique Active Lesions (CUAL) Per Year From Baseline to Week 108 | 1.405 (1.215 to 1.624) | 3.164 (2.757 to 3.631) |
A 12-week CDA was defined as an increase of at least 1.5 in Expanded Disability Status Scale (EDSS) for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score greater than or equal to (\>=) 5.5, which was confirmed after 12 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS).
| Percentage of Participants | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| 60 Weeks- from Kaplan Meier estimates | 7.6 (5.7 to 10.2) | 8.3 (6.3 to 11.0) |
| 108 Weeks- from Kaplan Meier estimates | 10.8 (8.4 to 13.7) | 13.2 (10.6 to 16.3) |
A 24-week CDA was defined as an increase of at least 1.5 in EDSS for participants with a baseline EDSS score of 0.0 or an increase of at least 1.0 in EDSS for participants with a baseline EDSS score of 1.0 to 5.0, or an increase of at least 0.5 in EDSS for participants with a baseline EDSS score \>= 5.5, which was confirmed after 24 weeks. Baseline EDSS was defined as the last EDSS score recorded prior to randomization. The EDSS is an ordinal scale ranging from 0 (normal neurological exam) to 10 (death to MS).
| Percentage of Participants | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| 60 Weeks- from Kaplan Meier estimates | 6.3 (4.6 to 8.7) | 6.9 (5.0 to 9.3) |
| 108 Weeks- from Kaplan Meier estimates | 8.7 (6.6 to 11.4) | 10.5 (8.2 to 13.4) |
Collected over Up to 111 Weeks (From treatment start [Day 1] to end of treatment [Week 108] plus 15 days). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponesimod 20 mg | 0/565 (0%) | 49/565 (8.7%) | 434/565 (76.8%) |
| Teriflunomide 14 mg | 2/566 (0.4%) | 46/566 (8.1%) | 422/566 (74.6%) |
| Event | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Abdominal PainGastrointestinal disorders | 3/565 | 0/566 |
| AppendicitisInfections and infestations | 3/565 | 0/566 |
| CholelithiasisHepatobiliary disorders | 1/565 | 3/566 |
| Lumbar RadiculopathyNervous system disorders | 2/565 | 1/566 |
| Abortion InducedSurgical and medical procedures | 2/565 | 0/566 |
| ConcussionInjury, poisoning and procedural complications | 0/565 | 2/566 |
| Alanine Aminotransferase IncreasedInvestigations | 0/565 | 2/566 |
| Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/565 | 2/566 |
| MetrorrhagiaReproductive system and breast disorders | 0/565 | 2/566 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/565 | 0/566 |
| Event | Ponesimod 20 mg | Teriflunomide 14 mg |
|---|---|---|
| Alanine Aminotransferase IncreasedInvestigations | 110/565 | 51/566 |
| NasopharyngitisInfections and infestations | 109/565 | 95/566 |
| HeadacheNervous system disorders | 64/565 | 72/566 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/565 | 72/566 |
| Upper Respiratory Tract InfectionInfections and infestations | 60/565 | 59/566 |
| NauseaGastrointestinal disorders | 43/565 | 47/566 |
| HypertensionVascular disorders | 45/565 | 44/566 |
| DiarrhoeaGastrointestinal disorders | 20/565 | 44/566 |
| Back PainMusculoskeletal and connective tissue disorders | 33/565 | 38/566 |
| FatigueGeneral disorders | 34/565 | 37/566 |
| Age, Continuous(years) | Ponesimod 20 mg | Teriflunomide 14 mg | Total |
|---|---|---|---|
| Mean | 36.7 ± 8.74 | 36.8 ± 8.74 | 36.7 ± 8.74 |
| Sex: Female, Male(Participants) | Ponesimod 20 mg | Teriflunomide 14 mg | Total |
|---|---|---|---|
| Female | 363 | 372 | 735 |
| Male | 204 | 194 | 398 |
| Race (NIH/OMB)(Participants) | Ponesimod 20 mg | Teriflunomide 14 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 551 | 553 | 1104 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 10 | 23 |
| Region of Enrollment(Participants) | Ponesimod 20 mg | Teriflunomide 14 mg | Total |
|---|---|---|---|
| BELARUS | 21 | 24 | 45 |
| BULGARIA | 18 | 27 | 45 |
| CANADA | 10 | 7 | 17 |
| CROATIA | 14 | 20 | 34 |
| CZECH REPUBLIC | 55 | 46 | 101 |
| FINLAND | 4 | 3 | 7 |
| FRANCE | 8 | 8 | 16 |
| GEORGIA | 24 | 17 | 41 |
| GERMANY | 9 | 7 | 16 |
| GREECE | 9 | 6 | 15 |
| HUNGARY | 7 | 12 | 19 |
| ISRAEL | 4 | 9 | 13 |
| ITALY | 7 | 7 | 14 |
| LATVIA | 11 | 4 | 15 |
| LITHUANIA | 3 | 8 | 11 |
| MEXICO | 7 | 10 | 17 |
| POLAND | 80 | 71 | 151 |
| PORTUGAL | 10 | 10 | 20 |
| ROMANIA | 10 | 5 | 15 |
| RUSSIAN FEDERATION | 116 | 111 | 227 |
| SPAIN | 34 | 39 | 73 |
| SWEDEN | 8 | 6 | 14 |
| TURKEY | 2 | 0 | 2 |
| UKRAINE | 57 | 66 | 123 |
| UNITED KINGDOM | 2 | 5 | 7 |
| UNITED STATES | 22 | 17 | 39 |
| Serbia | 14 | 19 | 33 |
| Bosnia | 1 | 2 | 3 |
Showing the first 100 of 162 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in May 2019, 47 months.
Results were first posted in Jun 2021, 2 years after primary completion. A results delay was requested in May 2020.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 47 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponesimod